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hematology-oncology- journal /EditorialPorphyria and implication of molecular diagnosisThe ﬁrst issue of the journal carried an article on Porphyria
Cutanea Tarda (PCT) [1]. This issue has a letter by Vieira in reference
to the article [2]. Vieira from Brazil has suggested an alternative
diagnosis to the described case of PCT by Patil et al. [1,2]. It is inter-
esting to note what Patil et al. have described to be a case of PCT
(the most common porphyria), is essentially a case of Hepatoery-
thopoietic Porphyria (HEP). HEP is an extremely rare form of cuta-
neous porphyria [3].
Porphyria is a disorder of heme biosynthesis. There are eight en-
zymes involved in heme biosynthesis; correspondingly, there are
eight genetically distinct porphyrias caused by the deﬁciency/deﬁ-
cient activity of the respective enzymes. Balwani and Desnick
(2012) have described a relatively simple classiﬁcation of por-
phyrias as: a) 4 acute hepatic, b) 1 hepatic cutaneous, and c) 3
erythropoietic cutaneous types [4]. The classiﬁcation aids in
remembering the predominant tissue where the heme metabolites
accumulate and the associated symptomatology. The porphyrias
manifest with varied and vague symptoms. Acute hepatic por-
phyrias typically present with intermittent neurologic attacks,
commonly abdominal pain. The hepatic-cutaneous porphyrias pre-
sent with photosensitive dermatitis and its sequelae. The erythro-
cutaneous porphyrias are characterized by photosensitive
dermatitis and hemolytic anemia. Porphyrias are rare disorders;
the prevalence of the most common one, PCT, is reported as 1 in
10,000. Indeed, a high degree of suspicion is required to suspect
and subsequently conﬁrm a case of porphyria [5].
Traditionally, urinary, plasma, fecal and/or erythrocyte
‘porphyrin proﬁle’ and enzyme activity level is performed to
screen/conﬁrm the diagnosis of porphyria. Molecular pathology
(genetic diagnosis) of porphyrias is a signiﬁcant advancement.
Molecular diagnosis is applicable when a known mutation, recur-
rently associated with the disease is detected. For novel mutations,
a correlation with tissue ‘porphyrin proﬁle’ and level of enzyme ac-
tivity is desirable. This diagnostic detail is an important consider-
ation, as genetic heterogeneity has been noted with porphyrias.
Greater than 375 and 105 mutations have been documented till
date, in Acute Intermittent Porphyria (AIP) and PCT, respectively
[6]. Another signiﬁcant application of genetic diagnosis is for pre-
natal diagnosis. In 2002, Ged et al. provided the ﬁrst description
of prenatal exclusion of HEP in a family [7]. HEP is a type of
hepato-cutaneous porphyria, with severe deﬁciency of uropor-
phyrinogen decarboxylase (UROD) enzyme. It results fromPeer review under responsibility of Pediatric Hematology Oncology Chapter of In-
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atic carrier parents. HEP typically manifests below 2 years of age
and is a severe mutilating disease [8]. The ability to offer a prenatal
diagnosis in such families is extremely satisfying.
As molecular diagnosis of porphyria becomes increasingly
feasible, an understanding of genetics of porphyrias is the need of
the hour. This is the observation of Vieira from Brazil as well, while
suggesting the alternative diagnosis of HEP for the described case of
PCT by Patil et al. [1,2]. PCT, as well as HEP are caused by deﬁciency
of uroporphyrinogen decarboxylase (UROD) enzyme. PCT, as the
name ‘tarda’ implies, typically presents late, in 4th or 5th decade
of life. Three types are described. Familial PCT (type II) is caused
by heterozygousmutation of UROD gene; the level of enzyme activ-
ity is reduced to ~50% of normal. During a symptomatic period, the
levels are further reduced to less than 20%. On the other hand, HEP
results from a biallelic UROD genemutation. Both the alleles/copies
of the gene are mutated, leading to profound deﬁciency of enzyme
and an earlier presentation. In the case described by Patil et al. the
symptoms begin at the age of two years and a homozygous muta-
tion of the UROD gene was detected. Hence it's a case of HEP rather
than PCT, as clariﬁed by Vieira [2].
Though porphyrias are genetic disorders, environmental factors
play a role in precipitating acute attacks. A useful resource for the
list of unsafe and safe drugs for patients with the acute hepatic por-
phyrias is available at the Drug Database for Acute Porphyrias
(www.drugs-porphyria.com). Similarly, several susceptibility fac-
tors are known for PCT. Avoiding incriminated precipitating factors,
such as alcohol, estrogens and iron supplements is recommended
[4].
Treatment strategies for porphyrias vary from simple avoidance
of sun exposure to as demanding as liver and bone marrow trans-
plantation. A lot comes under the purview of a hematologist,
including hematin infusions, phlebotomies and iron chelation.
Research and experimental studies are being pursued to manage
porphyria in novel ways, including recombinant enzyme (Porpho-
zym for AIP), chaperones and/or protease inhibitor to rescue en-
zymes [9,10]. Ultimately, gene therapy remains the ﬁnal promise
to provide a cure. Recently, a favorable, though heterogeneous
impact in a phase I gene therapy trial for AIP was observed; hema-
tin treatment could be stopped in 2 of 8 patients [11]. Though the
results of recent trials appear to be modest, it is optimistic, as
“Big things have small beginnings”.
Indeed, porphyrias have a varied presentation. An accurate diag-
nosis necessitates a correlation of the clinical presentation, tissue
‘porphyrin proﬁle’, level of enzyme activity, besides molecular
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